We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

182 hedge funds and large institutions have $1.3B invested in Pacira BioSciences in 2016 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 60 increasing their positions, 59 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

107.68% more ownership

Funds ownership: 0% → 107.68% (+108%)

13% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 31

1% more funds holding

Funds holding: 180 → 182 (+2)

5% more call options, than puts

Call options by funds: $23.8M | Put options by funds: $22.6M

2% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 59

4% less capital invested

Capital invested by funds: $1.35B → $1.3B (-$47.4M)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
182
Holders Change
+2
Holders Change %
+1.11%
% of All Funds
4.55%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.1%
New
35
Increased
60
Reduced
59
Closed
31
Calls
$23.8M
Puts
$22.6M
Net Calls
+$1.23M
Net Calls Change
-$6.98M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$38.7M
2
Millennium Management
Millennium Management
New York
+$29.7M
3
HM
HealthCor Management
New York
+$27.7M
4
CCM
Consonance Capital Management
New York
+$21.1M
5
WRF
Waddell & Reed Financial
Kansas
+$18.7M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$85M
2
Citadel Advisors
Citadel Advisors
Florida
-$41.1M
3
NCGI
Next Century Growth Investors
Minnesota
-$26.6M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$26.6M
5
Goldman Sachs
Goldman Sachs
New York
-$16.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
KT
176
Kanaly Trust
Texas
$2K -$1.4K -42 -39%
PG
177
Patten Group
Tennessee
$2K – – –
SF
178
Synovus Financial
Georgia
$2K +$2.17K +65 New
BFM
179
Boothbay Fund Management
New York
$1.47K +$336K +10,078 New
GWM
180
Geneos Wealth Management
Colorado
$1K – – –
NCGI
181
Next Century Growth Investors
Minnesota
– -$26.6M -778,442 Closed
SCM
182
Sarissa Capital Management
Connecticut
– -$14.7M -430,000 Closed
IHM
183
Iguana Healthcare Management
New York
– -$5.13M -150,000 Closed
HCM
184
Highbridge Capital Management
New York
– -$1.91M -55,872 Closed
Allianz Asset Management
185
Allianz Asset Management
Germany
– -$1.82M -53,137 Closed
CCMH
186
Cornerstone Capital Management Holdings
New York
– -$1.79M -52,300 Closed
FHAM
187
Folger Hill Asset Management
New York
– -$1.62M -48,639 Closed
Capital Fund Management (CFM)
188
Capital Fund Management (CFM)
France
– -$1.31M -38,346 Closed
Squarepoint
189
Squarepoint
New York
– -$978K -28,592 Closed
IA
190
Icon Advisers
Colorado
– -$787K -23,000 Closed
TI
191
Trexquant Investment
Connecticut
– -$712K -20,800 Closed
Wolverine Trading
192
Wolverine Trading
Illinois
– -$685K -20,539 Closed
TAM
193
Tocqueville Asset Management
New York
– -$520K -15,200 Closed
FRM
194
Fox Run Management
Connecticut
– -$459K -13,400 Closed
Marshall Wace
195
Marshall Wace
United Kingdom
– -$368K -10,749 Closed
JG
196
Jefferies Group
New York
– -$367K -10,721 Closed
ECM
197
Endurant Capital Management
California
– -$359K -10,500 Closed
BCM
198
Bayesian Capital Management
New York
– -$320K -9,350 Closed
DTL
199
Dynamic Technology Lab
Singapore
– -$319K -9,300 Closed
RCAMU
200
Rothschild & Co Asset Management US
Connecticut
– -$244K -7,137 Closed
5 6 7
8
9

PCRX Hedge Fund Activity: Q4 2016 in Review

182 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2016, worth a combined $1.3B — down 3.5% from $1.35B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new PCRX positions and 31 closed out — a net gain of 4 holders — while 60 added to existing stakes and 59 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $38.7M. The largest seller was Fidelity Investments, cutting an estimated $85M.

  • 182 institutional investors held Pacira BioSciences (PCRX) as of Q4 2016, up from 180 in Q3 2016.
  • Funds reported $1.3B of Pacira BioSciences stock for Q4 2016, down 3.5% quarter-over-quarter.
  • 35 funds opened new Pacira BioSciences positions in Q4 2016 and 31 closed out, a net change of +4 holders.
  • The largest Pacira BioSciences buyer in Q4 2016 was PFM Health Sciences, an estimated $38.7M added.
  • The largest Pacira BioSciences seller in Q4 2016 was Fidelity Investments, an estimated $85M sold.

Based on aggregated 13F filings for Q4 2016.